|Document ID (ISN)||77531|
|Convention or series no.
Inter-Organization Programme for the Sound Management of Chemicals (IOMC)
||Diphenylmethane diisocyanate (MDI)
||World Health Organization, Distribution and Sales Service, 1211 Genève 27, Switzerland, 2001. iv, 32p. 107 ref. Price: CHF 16.00 (CHF 11.20 in developing countries).
||http://www.who.int/ipcs/publications/cicad/en/cicad27.pdf [in English]
||Monomeric and polymeric diphenylmethane diisocyanate (MDI) are used for the manufacturing of polyurethane elastomers, rigid and flexible foams, and binders and adhesives. In the presence of water, MDI is rapidly hydrolysed to methylenedianiline (MDA). MDI is not acutely toxic to laboratory animals. Animal data provides clear evidence of skin and respiratory sensitization to MDI. In a two-year chronic inhalation toxicity and carcinogenicity study, changes in the respiratory tract of rats were observed, but carcinogenicity data were inconclusive. The IARC classification for MDI is 3 (not classifiable as to its carcinogenicity in humans), while MDA is classified 2B (possibly carcinogenic to humans). The health effects of most concern are occupationally-induced asthma, hypersensitivity pneumoconiosis and inflammatory diseases of the upper respiratory tract. Summaries in French and Spanish.
||diphenylmethane diisocyanate; toxicology; IPCS
||toxic effects; criteria document; irritants; methylenedianiline; upper respiratory tract; ILO; UNEP; WHO; asthma; ecotoxicology; animal experiments; lethal concentration 50; hypersensitivity; carcinogenic effects; literature survey
||B - Chemical safety information sheets
|Country / State or Province||WHO|
||Toxic and dangerous substances
|Broad subject area(s)